Literature DB >> 12891606

Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis.

Robert T Sperling1, Duane S Pinto, Kalon K L Ho, Joseph P Carrozza.   

Abstract

We report the time course to the restoration of normal platelet aggregation in three patients who were treated with eptifibatide in the setting of severe renal failure. There was prolonged platelet inhibition in the first patient who developed acute renal failure. The second patient with acute on chronic renal failure developed an intracerebral hemorrhage. Normal platelet aggregation was restored after acute hemodialysis. In a third patient with end-stage renal disease, platelet function returned to the normal range following hemodialysis. There is a prolonged time course to the restoration of normal platelet aggregation in patients with severe renal dysfunction who are treated with eptifibatide. Acute renal hemodialysis may reverse the inhibitory effect of eptifibatide on platelet aggregation in these patients. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12891606     DOI: 10.1002/ccd.10576

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  4 in total

1.  Drug therapy in kidney disease.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2007-05       Impact factor: 4.335

2.  Medication errors in patients with severe chronic kidney disease and acute coronary syndrome: the impact of computer-assisted decision support.

Authors:  Richard V Milani; Sylvia A Oleck; Carl J Lavie
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

3.  The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).

Authors:  Devraj Sukul; Milan Seth; Theodore Schreiber; George Hanzel; Akshay Khandelwal; Louis A Cannon; Thomas A Lalonde; Hitinder S Gurm
Journal:  J Interv Cardiol       Date:  2017-05-22       Impact factor: 2.279

Review 4.  The Role of Renal Replacement Therapy in the Management of Pharmacologic Poisonings.

Authors:  Aibek E Mirrakhimov; Aram Barbaryan; Adam Gray; Taha Ayach
Journal:  Int J Nephrol       Date:  2016-11-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.